---
schema_version: "secwatch.filing_event.v1"
accession: "0001932393-23-000004"
form_type: "8-K"
ticker: "GEHC"
cik: "0001932393"
company_name: "GE HealthCare Technologies Inc."
filed_at: "2023-01-10T23:59:59+00:00"
generated_at: "2026-06-20T17:18:17.728581+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# GE HealthCare preliminary Q4 revenue ~$4.9B (+7% YoY); 2023 organic growth guidance 5-7%

## Summary
- Q4 2022 revenue ~$4.9B, up ~7% YoY; organic revenue growth ~12% YoY.
- Full-year 2022 revenue ~$18.3B, up ~4% YoY; organic revenue growth ~7% YoY.
- Full-year 2022 adjusted EBIT above outlook; free cash flow toward low end of guidance.
- 2023 outlook: organic revenue growth 5-7%; adjusted EBIT margin 15.0-15.5% (up 50-100 bps).
- 2023 free cash flow conversion guidance of 85%+.

## SEC filing metadata
- accession: 0001932393-23-000004
- form_type: 8-K
- ticker: GEHC
- cik: 0001932393
- company_name: GE HealthCare Technologies Inc.
- filed_at: 2023-01-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1932393/000193239323000004/0001932393-23-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1932393/000193239323000004/gehc-20230106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001932393-23-000004
- JSON: https://secwatch.observer/filing/0001932393-23-000004.json
- Plain text: https://secwatch.observer/filing/0001932393-23-000004.txt

## Key facts
- Earnings Releases
  GE HealthCare Technologies Inc. reported fourth quarter and fiscal year ended December 31, 2022 results: revenue approximately $4.9 billion. Guidance initiated.
  - Period: fourth quarter and fiscal year ended December 31, 2022
  - Revenue: approximately $4.9 billion
  - Guidance: initiated
  - Result: preliminary results
  source text: solve some of the most significant clinical challenges with our precision care strategy.” Preliminary Fourth Quarter 2022 Results Fourth quarter 2022 revenue was approximately $4.9 billion. Revenue growth for the quarter was approximately 7% year over year. Organic revenue growth* for the quarter was approximately 12% year over year. Unless stated otherwise, all
  evidence_url: https://www.sec.gov/Archives/edgar/data/1932393/000193239323000004/0001932393-23-000004-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.